Oncolytics Biotech Inc. (ONCY)
|52 Week Range||1.09-3.39|
|1y Target Est||-|
|DCF Unlevered||ONCY DCF ->|
|DCF Levered||ONCY LDCF ->|
|Debt / Equity||2.15%||Neutral|
Upgrades & Downgrades
Latest ONCY news
3 Under-$20 Stocks to Buy for Explosive Returns
21 August 2023
A handful of stocks to buy under $20 can offer investors explosive returns in uncertain market conditions. The article lists names that might not immediately grab headlines, but their strategic focus ...
After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (O...
17 August 2023
The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St...
Oncolytics Biotech Inc. (ONCY) Q2 2023 Earnings Call Transcript
14 August 2023
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET Company Participants Jon Patton - Director-Investor Relations and Communications Matt Coffey - Presid...
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent O...
4 August 2023
Conference call and webcast to take place on Monday, August 14, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Aug. 4, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today ...
Oncolytics: Proof Of Concept In 2 Large Market Indications
3 July 2023
Positive results achieved, in using pelareorep + paclitaxel for the treatment of HR+/HER2- metastatic breast cancer patients, in the phase 2 BRACELET-1 study. Preparation is underway to initiate a pha...
Oncolytics Biotech's stock soars 25% after pelareorep is selected for inclusion in late-stage pancre...
22 June 2023
The stock of Oncolytics Biotech Inc. ONCY, +23.25% soared 25% Thursday, after the San Diego-based company said its pelareorep therapy has been selected for inclusion in a an adaptive phase 3 pancreati...
Oncolytics Biotech Inc. (ONCY) Q1 2023 Earnings Call Transcript
5 May 2023
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ET Company Participants Jon Patton – Director-Investor Relations and Communications Matt Coffey – Chief Exec...
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncolo...
12 April 2023
SAN DIEGO and CALGARY, AB , April 12, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Medical Officer Thomas Heineman, M.D., Ph.D., will participate ...
Oncolytics Biotech Inc. (ONCY) Q4 2022 Earnings Call Transcript
3 March 2023
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q4 2022 Earnings Conference Call March 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, Investor Relations and Communications Matt Coffey - Chief E...